A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tenofovir Alafenamide (VEMLIDY)

First FDA approval2016-11-10
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$308.8M in CY2024 Part D spend197K claims · 29K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.331/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$26.13
Across all dosage forms in distribution.
Highest NADAC
$51.93
Wide spread — brand-strength NDCs still in market.
Plans with PA
22 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Tenofovir Alafenamide used for?

Tenofovir Alafenamide is a this drug class medication tracked in Medicare Part D.

Is there a generic for Tenofovir Alafenamide?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Tenofovir Alafenamide?

Across 329 Part D plans, Tenofovir Alafenamide averages $26.13/unit (NADAC). Lowest available: $0.331/unit. Highest in distribution: $51.93/unit.

Is Tenofovir Alafenamide on the FDA shortage list?

No. Tenofovir Alafenamide is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.